Figure 4
Figure 4. PAR1ap or PAR2ap enhance infection and receptor desensitization affects coagulation protease-mediated infection. (A) HUVECs were inoculated with HSV1 (TF+/gC+, 4.5 × 105 vp/mL) in the presence of PAR1ap (10μM), PAR1/2ap (10μM), or PAR2ap (200μM) in SFM. The data were corrected for the amount of infection in the absence of added peptide (n = 4; data are ± SEM). *P ≤ .05 compared with no PARap. As in panel A except afterward, thrombin (10nM; B) or FXa (1nM; C) was added for 90 minutes. The data were corrected for the amount of infection without added protease or PARap (n = 6; data are ± SEM). *P ≤ .05 compared with the addition of protease.

PAR1ap or PAR2ap enhance infection and receptor desensitization affects coagulation protease-mediated infection. (A) HUVECs were inoculated with HSV1 (TF+/gC+, 4.5 × 105 vp/mL) in the presence of PAR1ap (10μM), PAR1/2ap (10μM), or PAR2ap (200μM) in SFM. The data were corrected for the amount of infection in the absence of added peptide (n = 4; data are ± SEM). *P ≤ .05 compared with no PARap. As in panel A except afterward, thrombin (10nM; B) or FXa (1nM; C) was added for 90 minutes. The data were corrected for the amount of infection without added protease or PARap (n = 6; data are ± SEM). *P ≤ .05 compared with the addition of protease.

Close Modal

or Create an Account

Close Modal
Close Modal